- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04291144
Visualising Cerebral and Peripheral Cholinergic Nerves in Patients With Dementia Lewy Bodies.
Visualising the Cerebral Cholinergic Innervation and Parasympathetic Gastrointestinal Nerves in Patients With Dementia Lewy Bodies.
Study Overview
Status
Detailed Description
Dementia with Lewy Bodies (DLB) is the second most common type of neurodegenerative dementia after Alzheimer's disease. It is characterized by cognitive decline, cognitive fluctuations, visual hallucinations, parkinsonism, and sleep disturbances. There is evidence of cholinergic neuron loss in the cerebrum of DLB patients, and Lewy body pathology in the cholinergic parasympathetic nerves of internal organs. A novel tracer, 18F-fluoroethoxybenzovesamicol (18F-FEOBV), binds to the cholinergic vesicle transporter, a protein expressed uniquely in the vesicles of cholinergic pre-synapses, and therefore a very specific marker for cholinergic innervation. There is only one previous FEOBV publication in DLB (4 patients). That study showed impressive imaging quality, far better than earlier cholinergic PET-ligands, such as 11C-donepezil. Per Borghammer has pioneered the use of 11C-donepezil PET to visualize cholinergic loss, and 18F-FEOBV PET represents the next generation of high-resolution cholinergic imaging. The aim is to investigate the cholinergic denervation in patients with DLB using 18F-FEOBV. The investigators hypothesize that, compared to healthy elderly controls, patients with DLB show: (i) Cholinergic denervation in cortical and subcortical structures of the brain, and in peripheral organs, specifically the gut, pancreas, and heart. (ii) Correlations between cerebral cholinergic denervation and cognitive decline, assessed with neuropsychometric measures. (iii) Correlations between cholinergic denervation of internal organs and relevant symptoms of autonomic dysfunction, e.g. orthostatic hypotension and constipation, and with objective measures of autonomic malfunction, e.g. increased colonic transit time, increased intestinal volume, and reduced heart rate variability. (iv) Thinning of the vagal nerve detected by ultra sound. (v) Correlations between cerebral cholinergic denervation and perturbed neural networks measured by functional MRI. Secondary aims are to compare the cerebral uptake of 18F-FEOBV in DLB patients with/without markers of Alzheimer's Disease in the cerebrospinal fluid, relate the pattern of glucose uptake (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose, 18F-FDG PET) to that of 18F-FEOBV uptake in the cerebrum, and contribute to development of a diagnostic alpha-synuclein assay.
The investigators plan to include 25-30 DLB patients and 20 matched healthy elderly controls. Patients are recruited from the dementia clinic, Aarhus University. Inclusion criteria are mild to moderate DLB, ability to give informed consent, and typical signs of DLB on an 18F-FDG-PET scan. Exclusion criteria are major psychiatric, neurologic and medical comorbidities. The investigators will do a clinical assessment including full somatic and neurological examinations, an extensive neuropsychological cognitive assessment, assess autonomic symptoms and evaluate for sleep disorders, test for orthostatic hypotension and heart rate variability and colonic transit time. The investigators will inject 300 megabecquerel (MBq) of 18F-FEOBV in a peripheral vein and scan the internal organs from 0-70 minutes. The patient then rests, and from 180-210 minutes post-injection, the brain is imaged. This two-step method has been validated to give a robust estimate of the cholinergic innervation of the brain. The investigators will also do magnetic resonance imaging of the brain, ultrasound of vagal nerve, cerebrospinal fluid analysis and blood work. The investigators plan to write a manuscript describing the cerebral uptake of 18F-FEOBV as measure of cholinergic denervation of patients with DLB. A second manuscript will describe the uptake of 18F-FEOBV in the internal organs. A third manuscript will compare the cholinergic denervation of brain and organs to cognitive and autonomic symptoms. NO will participate in recruitment of patients, drafting of protocol and manuscripts, organizing logistics, analysis of data, and collecting clinical and paraclinical data. The investigators will pay particular attention the ethical issues of obtaining informed consent from demented persons and emphasize an evaluation of competence. The investigators expect that this method is better than the currently used 11C-donepezil, in which case it will replace its use for studies of cholinergic denervation in the future. Developing non-invasive PET imaging of short duration is particularly important in a demented patient population that often struggle to lie still during prolonged scanning sessions. Development of strong objective measures to aid diagnosis of DLB is important because DLB is a common disease projected to increase even further in prevalence in the years to come. Also, our side project of contributing to the development of a prion-assay to detect alpha-synuclein in the cerebrospinal fluid has promising clinical potential.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Niels Okkels, MD
- Phone Number: +4528530637
- Email: niels.okkels@clin.au.dk
Study Contact Backup
- Name: Per Borghammer, MD, DMSc
- Phone Number: +4528261039
- Email: borghammer@clin.au.dk
Study Locations
-
-
-
Aarhus N, Denmark, 8200
- Department of Nuclear medicine and PET, Aarhus University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- mild to moderate DLB, ability to give informed consent, and typical signs of DLB on an FDG-PET or dopamine transporter (DaT)-scan
Exclusion Criteria:
- schizophrenia, bipolar disorder, cerebral neoplasms, clinical stroke, diabetes, peripheral neuropathy, previous surgery or radiotherapy on cerebrum or internal organs, gastrointestinal inflammatory disease, severe organ failure, allergy to CT-contrast media and contraindications to MRI-scans
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients
Inclusion criteria are mild to moderate DLB, age above 50, ability to give informed consent.
|
We will inject 300 MBq of 18F-FEOBV in a peripheral vein and scan the internal organs from (0-70 minutes).
The patient then rests, and from 180-210min after injection, we will scan the brain on our Siemens High Resolution Research Tomograph.
All patients will have an MRI scan of the brain.
T1-weighted images will be used to assess general anatomy and identify white matter.
T2-weighted sequences will be performed to quantify competing brain pathology.
Also, we will collect functional MRI data.
Full neuropsychometric examination including tests in 5 cognitive domains.
Age, sex, duration of disease, patient history and full somatic and neurological examinations.
Constipation assessed with Rome-III criteria.
Evaluation of Rapid Eye Movement (REM) sleep Behaviour Disorder (RBDSQ) questionnaire.
Test for orthostatic hypotension, heart rate variability, and deep breathing.
|
Healthy controls
Age above 50.
|
We will inject 300 MBq of 18F-FEOBV in a peripheral vein and scan the internal organs from (0-70 minutes).
The patient then rests, and from 180-210min after injection, we will scan the brain on our Siemens High Resolution Research Tomograph.
All patients will have an MRI scan of the brain.
T1-weighted images will be used to assess general anatomy and identify white matter.
T2-weighted sequences will be performed to quantify competing brain pathology.
Also, we will collect functional MRI data.
Full neuropsychometric examination including tests in 5 cognitive domains.
Age, sex, duration of disease, patient history and full somatic and neurological examinations.
Constipation assessed with Rome-III criteria.
Evaluation of Rapid Eye Movement (REM) sleep Behaviour Disorder (RBDSQ) questionnaire.
Test for orthostatic hypotension, heart rate variability, and deep breathing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cerebral density of vesicular acetylcholine transporter in patients compared to controls
Time Frame: Day 1
|
Average density will be determined in each group for relevant areas of the brain.
Group differences will be calculated
|
Day 1
|
Organ density of vesicular acetylcholine transporter in patients compared to controls
Time Frame: Day 1
|
Average density will be determined in each group for intestine, pancreas, suprarenal gland, and heart.
Group differences will be calculated
|
Day 1
|
Density of vesicular acetylcholine transporter compared to cognitive profile and autonomic symptoms.
Time Frame: Day 2
|
Obtain clinical information and perform standard neurologic and somatic evaluation and full neuropsychological assessment.
Relate density of tracer in brain and organs to corresponding cognitive and autonomic symptoms.
|
Day 2
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Per Borghammer, MD, DMSc, University of Aarhus
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DLB-FEOBV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia With Lewy Bodies
-
EIP Pharma IncWorldwide Clinical TrialsCompletedDementia With Lewy Bodies (DLB)United States, Netherlands
-
Osaka UniversityCompletedDementia With Lewy Bodies (DLB)Japan
-
Eisai Inc.CompletedDementias With Lewy BodiesUnited States
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
University Hospital, Strasbourg, FranceRecruitingDementia With Lewy Bodies Diagnosis | Significant Cognitive Fluctuations in DLBFrance
-
Eisai Co., Ltd.Completed
-
CND Life SciencesNational Institute on Aging (NIA)RecruitingMCI-AD, Early Stage Alzheimer's Disease | MCI-DLB, Early Stage Dementia With Lewy BodiesUnited States
-
Cognition TherapeuticsNational Institute on Aging (NIA)RecruitingDementia With Lewy BodiesUnited States
Clinical Trials on PET-CT using FEOBV
-
University of VermontTerminatedProstatic NeoplasmUnited States
-
University of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingParkinson Disease | Progressive Supranuclear PalsyUnited States
-
University Medical Center GroningenUnknownParkinson's DiseaseNetherlands
-
University of Alabama at BirminghamRecruitingIdiopathic Pulmonary FibrosisUnited States
-
Peter HovindNot yet recruitingMyocardial Blood FlowDenmark
-
Institute of Oncology LjubljanaActive, not recruitingMelanoma | PET CTSlovenia
-
Peter MacCallum Cancer Centre, AustraliaMelbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...CompletedAcute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, AllogeneicAustralia
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
HALO DiagnosticsCompletedProstate CancerUnited States